Nicotine Addiction Develops, to Inhale the Smoke Than Are Users of Cigars Only.5 Cigars It Is Useful to Understand Different Forms of Tobacco
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Smoking Cessation Treatment at Substance Abuse Rehabilitation Programs
SMOKING CEssATION TREATMENT AT SUBSTANCE ABUSE REHABILITATION PROGRAMS Malcolm S. Reid, PhD, New York University School of Medicine, Department of Psychiatry; Jeff Sel- zer, MD, North Shore Long Island Jewish Healthcare System; John Rotrosen, MD, New York University School of Medicine, Department of Psychiatry Cigarette smoking is common among persons with drug and alcohol n Nicotine is a highly use disorders, with prevalence rates of 80-90% among patients in sub- addictive substance stance use disorder treatment programs. Such concurrent smoking may that meets all of produce adverse behavioral and medical problems, and is associated the criteria for drug with greater levels of substance use disorder. dependence. CBehavioral studies indicate that the act of cigarette smoking serves as a cue for drug and alcohol craving, and the active ingredient of cigarettes, nicotine, serves as a primer for drug and alcohol abuse (Sees and Clarke, 1993; Reid et al., 1998). More critically, longitudinal studies have found tobacco use to be the number one cause of preventable death in the United States, and also the single highest contributor to mortality in patients treated for alcoholism (Hurt et al., 1996). Nicotine is a highly addictive substance that meets all of the criteria for drug dependence, and cigarette smoking is an especially effective method for the delivery of nicotine, producing peak brain levels within 15-20 seconds. This rapid drug delivery is one of a number of common properties that cigarette smok- ing shares with hazardous drug and alcohol use, such as the ability to activate the dopamine system in the reward circuitry of the brain. -
Drug Facts Cigarettes and Other Tobacco Products
Cigarettes and Other Tobacco Products Tobacco use is the leading preventable cause smokes about 1 pack (25 cigarettes) daily of disease, disability, and death in the United gets 250 “hits” of nicotine each day. States. According to the Centers for Disease Control and Prevention (CDC), cigarette Upon entering the bloodstream, nicotine smoking results in more than 480,000 immediately stimulates the adrenal glands premature deaths in the United States each to release the hormone epinephrine year—about 1 in every 5 U.S. deaths—and an (adrenaline). Epinephrine stimulates the additional 16 million people suffer with a central nervous system and increases blood serious illness caused by smoking. In fact, for pressure, respiration, and heart rate. every one person who dies from smoking, about 30 more suffer from at least one Similar to other addictive drugs like cocaine serious tobacco-related illness.1 and heroin, nicotine increases levels of the neurotransmitter dopamine, which affects The harmful effects of smoking extend far the brain pathways that control reward and beyond the smoker. Exposure to secondhand pleasure. For many tobacco users, long- smoke can cause serious diseases and death. term brain changes induced by continued Each year, an estimated 88 million nicotine exposure result in addiction—a nonsmoking Americans are regularly exposed condition of compulsive drug seeking and to secondhand smoke and almost 41,000 use, even in the face of negative nonsmokers die from diseases caused by consequences. Studies suggest that secondhand smoke exposure.1,2 additional compounds in tobacco smoke, such as acetaldehyde, may enhance How Does Tobacco Affect the Brain? nicotine’s effects on the brain.3 Cigarettes and other forms of tobacco— When an addicted user tries to quit, he or including cigars, pipe tobacco, snuff, and she experiences withdrawal symptoms chewing tobacco—contain the addictive including irritability, attention difficulties, drug nicotine. -
Alcohol, Tobacco, and Prescription Drugs: the Relationship with Illicit Drugs in the Treatment of Substance Users
Macquarie University ResearchOnline This is the author version of an article published as: Teesson, M., Farrugia, P., Mills, K., Hall, W., & Baillie, A. (2012). Alcohol, tobacco, and prescription drugs: The relationship with illicit drugs in the treatment of substance users. Substance use & misuse, Vol. 47, Issue 8-9, p. 963-971. Access to the published version: http://doi.org/10.3109/10826084.2012.663283 Copyright: Copyright the Publisher 2012. Version archived for private and non- commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher. Comorbidity 1 Alcohol, tobacco and prescription drugs: The relationship with illicit drugs in the treatment of substance users. Maree Teesson, Philippa Farrugia, Katherine Mills 1 Wayne Hall2, Andrew Baillie3. 1. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales 2052 Australia, 2. University of Queensland Centre for Clinical Research, 3. Centre for Emotional Health, Department of Psychology, Macquarie University. * Corresponding author: Maree Teesson National Drug and Alcohol Research Centre University of New South Wales, Sydney New South Wales 2052 Australia Tel: +61 2 9385 0333; fax: +61 2 9385 0222; email: [email protected] Abstract Alcohol, tobacco, prescription drug and illicit drug use frequently co-occur. This paper reviews the extent of this co-occurrence in both general population samples and clinical samples, and its impact on treatment outcome. We argue that the research base for understanding comorbidity between tobacco, alcohol, prescription and illicit drugs needs to be broadened. We specifically advocate for: 1) more epidemiological studies of relationships between alcohol, tobacco and other illicit drug use; and 2) increased research on treatment options that address the problematic use of all of these drugs. -
Neonatal Drug Withdrawal Abstract
Guidance for the Clinician in Rendering Pediatric Care CLINICAL REPORT Neonatal Drug Withdrawal Mark L. Hudak, MD, Rosemarie C. Tan, MD,, PhD, THE abstract COMMITTEE ON DRUGS, and THE COMMITTEE ON FETUS AND Maternal use of certain drugs during pregnancy can result in transient NEWBORN neonatal signs consistent with withdrawal or acute toxicity or cause KEY WORDS opioid, methadone, heroin, fentanyl, benzodiazepine, cocaine, sustained signs consistent with a lasting drug effect. In addition, hos- methamphetamine, SSRI, drug withdrawal, neonate, abstinence pitalized infants who are treated with opioids or benzodiazepines to syndrome provide analgesia or sedation may be at risk for manifesting signs ABBREVIATIONS of withdrawal. This statement updates information about the clinical CNS—central nervous system — presentation of infants exposed to intrauterine drugs and the thera- DTO diluted tincture of opium ECMO—extracorporeal membrane oxygenation peutic options for treatment of withdrawal and is expanded to include FDA—Food and Drug Administration evidence-based approaches to the management of the hospitalized in- 5-HIAA—5-hydroxyindoleacetic acid fant who requires weaning from analgesics or sedatives. Pediatrics ICD-9—International Classification of Diseases, Ninth Revision — – NAS neonatal abstinence syndrome 2012;129:e540 e560 SSRI—selective serotonin reuptake inhibitor INTRODUCTION This document is copyrighted and is property of the American fi Academy of Pediatrics and its Board of Directors. All authors Use and abuse of drugs, alcohol, and tobacco contribute signi cantly have filed conflict of interest statements with the American to the health burden of society. The 2009 National Survey on Drug Use Academy of Pediatrics. Any conflicts have been resolved through and Health reported that recent (within the past month) use of illicit a process approved by the Board of Directors. -
Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW
Guideline Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW Summary To provide the most up-to-date knowledge and current level of best practice for the treatment of withdrawal from alcohol and other drugs such as heroin, and other opioids, benzodiazepines, cannabis and psychostimulants. Document type Guideline Document number GL2008_011 Publication date 04 July 2008 Author branch Centre for Alcohol and Other Drugs Branch contact (02) 9424 5938 Review date 18 April 2018 Policy manual Not applicable File number 04/2766 Previous reference N/A Status Active Functional group Clinical/Patient Services - Pharmaceutical, Medical Treatment Population Health - Pharmaceutical Applies to Area Health Services/Chief Executive Governed Statutory Health Corporation, Board Governed Statutory Health Corporations, Affiliated Health Organisations, Affiliated Health Organisations - Declared Distributed to Public Health System, Ministry of Health, Public Hospitals Audience All groups of health care workers;particularly prescribers of opioid treatments Secretary, NSW Health Guideline Ministry of Health, NSW 73 Miller Street North Sydney NSW 2060 Locked Mail Bag 961 North Sydney NSW 2059 Telephone (02) 9391 9000 Fax (02) 9391 9101 http://www.health.nsw.gov.au/policies/ space space Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW space Document Number GL2008_011 Publication date 04-Jul-2008 Functional Sub group Clinical/ Patient Services - Pharmaceutical Clinical/ Patient Services - Medical Treatment Population Health - Pharmaceutical -
Concurrent Alcohol and Tobacco Dependence
Concurrent Alcohol and Tobacco Dependence Mechanisms and Treatment David J. Drobes, Ph.D. People who drink alcohol often also smoke and vice versa. Several mechanisms may contribute to concurrent alcohol and tobacco use. These mechanisms include genes that are involved in regulating certain brain chemical systems; neurobiological mechanisms, such as cross-tolerance and cross-sensitization to both drugs; conditioning mechanisms, in which cravings for alcohol or nicotine are elicited by certain environmental cues; and psychosocial factors (e.g., personality characteristics and coexisting psychiatric disorders). Treatment outcomes for patients addicted to both alcohol and nicotine are generally worse than for people addicted to only one drug, and many treatment providers do not promote smoking cessation during alcoholism treatment. Recent findings suggest, however, that concurrent treatment for both addictions may improve treatment outcomes. KEY WORDS: comorbidity; AODD (alcohol and other drug dependence); alcoholic beverage; tobacco in any form; nicotine; smoking; genetic linkage; cross-tolerance; AOD (alcohol and other drug) sensitivity; neurotransmitters; brain reward pathway; cue reactivity; social AODU (AOD use); cessation of AODU; treatment outcome; combined modality therapy; literature review lcohol consumption and tobacco ers who are dependent on nicotine Department of Health and Human use are closely linked behaviors. have a 2.7 times greater risk of becoming Services 1989). The concurrent use of A Thus, not only are people who alcohol dependent than nonsmokers both drugs by pregnant women can drink alcohol more likely to smoke (and (e.g., Breslau 1995). Finally, although also result in more severe prenatal dam- vice versa) but also people who drink the smoking rate in the general popula age and neurocognitive deficits in their larger amounts of alcohol tend to smoke tion has gradually declined over the offspring than use of either drug alone more cigarettes. -
Substance Abuse: the Pharmacy Educator’S Role in Prevention and Recovery
Substance Abuse: The Pharmacy Educator’s Role in Prevention and Recovery Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease i Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease1,2 BACKGROUND OF THE CURRICULUM DEVELOPMENT PROJECT In 1988, the AACP Special Interest Group (SIG) on Pharmacy Student and Faculty Impairment (renamed Substance Abuse Education and Assistance) undertook the development of curricular guidelines for colleges/schools of pharmacy to facilitate the growth of educational opportunities for student pharmacists. These Curricular Guidelines for Pharmacy Education: Substance Abuse and Addictive Disease were published in 1991 (AJPE. 55:311-16. Winter 1991.) One of the charges of the Special Committee on Substance Abuse and Pharmacy Education was to review and revise the 1991 curricular guidelines. Overall, the didactic and experiential components in the suggested curriculum should prepare the student pharmacist to competently problem-solve issues concerning alcohol and other drug abuse and addictive diseases affecting patients, families, colleagues, themselves, and society. The guidelines provide ten educational goals, while describing four major content areas including: psychosocial aspects of alcohol and other drug use; pharmacology and toxicology of abused substances; identification, intervention, and treatment of people with addictive diseases; and legal/ethical issues. The required curriculum suggested by these guidelines addresses the 1 These guidelines were revised by the AACP Special Committee on Substance Abuse and Pharmacy Education. Members drafting the revised guidelines were Edward M. DeSimone (Creighton University), Julie C. Kissack (Harding University), David M. Scott (North Dakota State University), and Brandon J. Patterson (University of Iowa). Other Committee members were Paul W. Jungnickel, Chair (Auburn University), Lisa A. -
Substance Abuse and Dependence
9 Substance Abuse and Dependence CHAPTER CHAPTER OUTLINE CLASSIFICATION OF SUBSTANCE-RELATED THEORETICAL PERSPECTIVES 310–316 Residential Approaches DISORDERS 291–296 Biological Perspectives Psychodynamic Approaches Substance Abuse and Dependence Learning Perspectives Behavioral Approaches Addiction and Other Forms of Compulsive Cognitive Perspectives Relapse-Prevention Training Behavior Psychodynamic Perspectives SUMMING UP 325–326 Racial and Ethnic Differences in Substance Sociocultural Perspectives Use Disorders TREATMENT OF SUBSTANCE ABUSE Pathways to Drug Dependence AND DEPENDENCE 316–325 DRUGS OF ABUSE 296–310 Biological Approaches Depressants Culturally Sensitive Treatment Stimulants of Alcoholism Hallucinogens Nonprofessional Support Groups TRUTH or FICTION T❑ F❑ Heroin accounts for more deaths “Nothing and Nobody Comes Before than any other drug. (p. 291) T❑ F❑ You cannot be psychologically My Coke” dependent on a drug without also being She had just caught me with cocaine again after I had managed to convince her that physically dependent on it. (p. 295) I hadn’t used in over a month. Of course I had been tooting (snorting) almost every T❑ F❑ More teenagers and young adults die day, but I had managed to cover my tracks a little better than usual. So she said to from alcohol-related motor vehicle accidents me that I was going to have to make a choice—either cocaine or her. Before she than from any other cause. (p. 297) finished the sentence, I knew what was coming, so I told her to think carefully about what she was going to say. It was clear to me that there wasn’t a choice. I love my T❑ F❑ It is safe to let someone who has wife, but I’m not going to choose anything over cocaine. -
Nicotine and Methylphenidate Chornic Exposure on Adult Cannabinoid Receptor Agonist (Cp 55,940) Place Conditioning in Male Rats
California State University, San Bernardino CSUSB ScholarWorks Electronic Theses, Projects, and Dissertations Office of aduateGr Studies 6-2016 NICOTINE AND METHYLPHENIDATE CHORNIC EXPOSURE ON ADULT CANNABINOID RECEPTOR AGONIST (CP 55,940) PLACE CONDITIONING IN MALE RATS Christopher P. Plant California State University - San Bernardino Follow this and additional works at: https://scholarworks.lib.csusb.edu/etd Part of the Biological Psychology Commons, and the Clinical Psychology Commons Recommended Citation Plant, Christopher P., "NICOTINE AND METHYLPHENIDATE CHORNIC EXPOSURE ON ADULT CANNABINOID RECEPTOR AGONIST (CP 55,940) PLACE CONDITIONING IN MALE RATS" (2016). Electronic Theses, Projects, and Dissertations. 339. https://scholarworks.lib.csusb.edu/etd/339 This Thesis is brought to you for free and open access by the Office of aduateGr Studies at CSUSB ScholarWorks. It has been accepted for inclusion in Electronic Theses, Projects, and Dissertations by an authorized administrator of CSUSB ScholarWorks. For more information, please contact [email protected]. NICOTINE AND METHYLPHENIDATE CHRONIC EXPOSURE ON ADULT CANNABINOID RECEPTOR AGONIST (CP 55,940) PLACE CONDITIONING IN MALE RATS A Thesis Presented to the Faculty of California State University, San Bernardino In Partial Fulfillment of the Requirements for the Degree Master of Arts in General-Experimental Psychology by Christopher Philip Plant June 2016 NICOTINE AND METHYLPHENIDATE CHRONIC EXPOSURE ON ADULT CANNABINOID RECEPTOR AGONIST (CP 55,940) PLACE CONDITIONING IN MALE -
Health Effects and Dependency Associated with Snuff Consumption
Health effects and dependency associated with snuff consumption This is an excerpt from the full technical report, which is written in Norwegian. The excerpt provides the report’s main messages in English. N0. 06–2005 Systematic reviews Title Health effects and dependency associated with snuff consumption Norwegian title Virkninger av snusbruk Institution Norwegian Knowledge Centre for the Health Services (Nasjonalt kunnskapssenter for helsetjenesten) John-Arne Røttingen, Director Authors Inger Natvig Norderhaug, Research manager Erik Dybing, Hans Gilljam, Petter O. Lind, Karl Erik Lund, Jørg Mørland, Birgitta Stegmayr, Bjørn Hofmann, Ida-Kristin Ørjasæter Elvsaas ISBN 82-8121-051-6 ISSN 1503-9544 Report No. 6 – 2005 Project number 5-207 Type of report Systematic reviews No. of pages 133 Client The Norwegian Directorate of Health Subject heading Tobacco, Smokeless; Dependency (Psychology) (MeSH) Keywords Snuff Citation Norderhaug IN, Dybing E, Gilljam H, Lind P O., Lund KE, Mørland J, Stegmayr B, Hofmann B, Ørjasæter Elvsaas I-K. Health effects and dependency associated with snuff consumption. Report from Kunnskapssenteret no. 6−2005. Oslo: Norwegian Knowledge Centre for the Health Services, 2005. Norwegian Knowledge Centre for the Health Services summarizes and disseminates evidence concerning the effect of treatments, methods, and interventions in health services, in addition to monitoring health service quality. Our goal is to support good decision making in order to provide patients in Norway with the best possible care. The Centre is organized under The Norwegian Directorate for Health, but is scientifically and professionally independent. The Centre has no authority to develop health policy or responsibility to implement policies. We would like to thank all contributers for their expertise in this project. -
Bacterial Contamination of Packaged Smokeless Tobacco Sold in India
Research Paper Tobacco Prevention & Cessation Bacterial contamination of packaged smokeless tobacco sold in India Rashmi Mehra1, Vikrant Mohanty1, Aswini Y. Balappanavar1, Shivam Kapoor1 ABSTRACT INTRODUCTION About 21.4% of India’s population uses smokeless tobacco products (SLT), yet limited data are available on their microbial contamination. To AFFILIATION understand the potential microbiological risks associated with SLT use, the 1 Department of Public Health present study aims to investigate bacterial contamination of tobacco and the Dentistry, Maulana Azad Institute of Dental Sciences, New Delhi, types of microbes that could be cultured from SLT products. India METHODS Twenty-two brands of SLT products, including paan masala, khaini, gutka and tobacco-containing dentifrices were examined and cultured by using CORRESPONDENCE TO Rashmi Mehra. Department of appropriate selective and differential media including MacConkey agar and CLED Public Health Dentistry, Maulana agar. This was followed by a sequence of further identification by biochemical Azad Institute of Dental Sciences, New Delhi, India. tests. E-mail: [email protected] RESULTS All 22 types of SLT products showed growth of aerobic bacteria. The most KEYWORDS common bacteria isolated were Pseudomonas aeruginosa followed by Streptococcus contamination, bacteria, faecalis. Other bacteria that were isolated from products, in traces, included toxicology, smokeless tobacco, Klebsiella spp., E. coli, and Bacillus subtilus. tobacco constituents CONCLUSIONS This study raises and -
Tobacco Use: a Smart Guide
1 Tobacco Use: A Smart Guide “STOPPING TAKES HARD WORK AND A LOT OF EFFORT, BUT – YOU CAN STOP TOBACCO” THE PROCESS OF QUITTING Do you find quitting tobacco difficult? The reason you continue to use tobacco is not because you are weak-willed or irresponsible, but because you are addicted. Nicotine is said to be more addictive than brown sugar (heroin) or cocaine. That is why people find it so difficult to stop, once they are habituated. The quitting process involves three steps: A. Preparation before quitting B. Actual quitting and C. Life after quitting. This manual will guide you through each of these steps. YOU NEED TO KNOW Before trying to quit tobacco you need to know a few facts about tobacco: • Tobacco comes in different forms….and all contain nicotine, the addictive substance. • Smoking forms of tobacco are beedis, cigarettes, cigars, chuttas, dhumti, pipe, hooklis, and hookah. • Smokeless forms of tobacco include chewing paan (betel quid) with zarda (tobacco), guthka, pan masala, manipuri tobacco, mawa, khaini, kaddi pudi, chewing tobacco leaves, mishri, gul, snuff, tobacco tooth paste and as tobacco water. Tobacco Facts • Tobacco is the leading cause of preventable death. • Each year tobacco kills 40,00,000 people. 2500 Indians die EVERYDAY due to tobacco related diseases. Deaths from tobacco use world wide are more than that from cocaine, heroin, alcohol, fires, accidents, murder, suicide, and AIDS COMBINED. • If you use tobacco, you are likely to die 15 years earlier. Tobacco Use: A Smart Guide 2 • Tobacco affects all the organs in the body from head to toe.